| 前收市價 | 7.90 |
| 開市 | 7.50 |
| 買盤 | 7.50 |
| 賣出價 | 12.70 |
| 拍板 | 217.50 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 7.50 - 7.90 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 5 |
ZacksAlzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
ZacksThe Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
ZacksThe Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
